A Bivalent Omicron-Containing Booster Vaccine against Covid-19
Spyros Chalkias(Moderna Therapeutics (United States)), Rituparna Das(Moderna Therapeutics (United States)), Keith Vrbicky(Meridian Clinical Research), Bethany Girard(Moderna Therapeutics (United States)), Nichole McGhee(Moderna Therapeutics (United States)), Stephen R. Walsh(Beth Israel Deaconess Medical Center), Charles Harper(Meridian Clinical Research), Joanne E. Tomassini(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xing Chen(Moderna Therapeutics (United States)), Jing Feng(Moderna Therapeutics (United States)), Jacqueline M. Miller(Moderna Therapeutics (United States)), Darin K. Edwards(Moderna Therapeutics (United States)), Andrea Sutherland(Moderna Therapeutics (United States)), Lindsey R. Baden(Brigham and Women's Hospital), Ying Chang(Moderna Therapeutics (United States)), David C. Montefiori(Duke University), Brandon Essink(Velocity Clinical Research (United States)), Adam Brosz(Meridian Clinical Research)
Cited by 649
Related Papers
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
|Cell|2020|4.5k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
|The Journal of Prevention of Alzheimer s Disease|2022|1.3k